CJC-1295 w/ DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid analog of growth hormone-releasing hormone (GHRH) developed by ConjuChem Biotechnologies. It features four amino acid substitutions from native GHRH (1-29) that enhance stability against enzymatic degradation.

The DAC component is a maleimido derivative of lysine that forms a covalent bond with serum albumin after injection, dramatically extending the peptide’s half-life from approximately 30 minutes to 6–8 days. This allows for once-weekly dosing in research protocols.

In clinical studies, a single injection of CJC-1295 DAC increased plasma growth hormone levels by 2- to 10-fold for up to 6 days and IGF-1 levels by 1.5- to 3-fold for 9–11 days. The compound reached Phase II clinical trials but was discontinued.

CJC-1295 is not approved by the FDA for any medical use. All products are sold strictly for laboratory and research purposes only.